2 billion

On January 18, NMPA's official website reported that Yangzijiang's propofol/long-chain fat emulsion class 4 imitation listing application was approved and evaluated as such.
meters intranet data show that propofol medium/long chain fat emulsion is China's public medical institutions terminal nearly 2 billion anaesthetic varieties, the product has been included in the fourth batch of national collection.
It is learned that propofol because of its fast effect, smooth induction, short duration, rapid awakening and complete, no accumulation and other advantages, has become the most commonly used intravenous anesthetic in the clinic, but propofol water solubility is poor, in order to improve solubility, currently listed in the world a total of 2 kinds of fat emulsion system: propofol injection (long-chain fat milk) and propofol medium/long chain fat emulsion.
propofol medium/ long-chain fat emulsion with partial chain triglycerides instead of long-chain triglycerides as a new carrier, further increased solubility, reduced free propofol content, and the metabolism of medium-chain triglycerides faster, clinical use can effectively reduce injection pain, reduce the risk of hyperlipidemia, reduce the burden on the liver.
Figure 1:2020H1 Propofol medium/long chain fat emulsion enterprise pattern Source: Minet China's public medical institutions terminal competition pattern Minet data show that in 2019 in China's urban public hospitals, county-level public hospitals, urban community centers and township hospitals (referred to as China's public medical institutions) terminal, propofol/long chain fat emulsion sales of nearly 2 billion yuan.
from the corporate landscape, under the impact of domestic generic drugs, the market share of the original Research Faison Yuscabi continued to decline, 2020H1 only 52.22 percent.
Figure 2: The current evaluation of propofol medium / long chain fat milk injection source: Minet MED 2.0 China Drug Review Database in October and November 2020, Jiangsu Yingke Biopharmaceuticals, Sichuan Colum Pharmaceuticals 4 types of imitations have been approved and treated as the same, this Yangzijiang also according to the new classification was approved and reviewed, successfully won the fourth batch of national "tickets."
Sichuan Guorui Pharmaceuticals, Guangdong Jiabo Pharmaceuticals, the consistency evaluation of supplementary applications are being reviewed and approved, if approved before the opening of the bid can also be qualified to bid.
we'll see who the breed ends up with will be the big winner.
source: NMPA official website, Minet database review data statistics as of January 18, 2021, if there are errors, please point out.